Please login to the form below

Not currently logged in
Email:
Password:

tetrabenazine

This page shows the latest tetrabenazine news and features for those working in and with pharma, biotech and healthcare.

FDA approves Teva's Huntington's disease drug at second attempt

FDA approves Teva's Huntington's disease drug at second attempt

The green light gives patients with HD in the US the first alternative to Lundbeck's already approved Xenazine (tetrabenazine) drug, which was launched onto the market in 2008. ... looking at symptom control in patients who switch to Teva's drug from

Latest news

  • FDA sets August review date for Teva's movement disorder drug FDA sets August review date for Teva's movement disorder drug

    Huntington's disease is a much smaller market than TD but that has not stopped the only approved drug for the condition - Lundbeck's Xenazine (tetrabenazine) - bring in sales of $330m

  • FDA turns down Teva's Huntington's disease drug FDA turns down Teva's Huntington's disease drug

    In a statement, Teva said that the metabolites under scrutiny by the FDA are not novel, and are also seen in patients who take tetrabenazine. ... It is estimated that because of tolerability issues only around 5% of eligible Huntington's disease patients

  • Teva drug shows promise in movement disorder Teva drug shows promise in movement disorder

    While there is no FDA-approved drug for TD, the drug from which Teva's candidate is derived - Lundbeck's Xenazine (tetrabenazine) - has been used off-label to treat symptoms but ... Tetrabenazine is approved as an orphan drug in the US to treat chorea

  • Teva starts M&A push with $3.5bn Auspex buy Teva starts M&A push with $3.5bn Auspex buy

    It is also relatively low risk, as the non-deuterated form of tetrabenazine is already sold as Xenazine by Lundbeck as a treatment for Huntington's and achieved sales of

  • Lundbeck still feeling effects from Cipralex patent loss Lundbeck still feeling effects from Cipralex patent loss

    Leading the upward trend was Xenazine (tetrabenazine) for the treatment of chorea associated with Huntington's disease - up 27% to 440m krone - and Onfi (clobazam) for Lennox-Gastaut syndrome which added

More from news
Approximately 1 fully matching, plus 13 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics